Other Guidelines | Page 39 | European Cystic Fibrosis Society (ECFS)

Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis

Do bone active therapy and lung disease influence the skeletal outcome after transplantation?

Using an Antibiotic Treatment Called Amikacin Liposome Inhalation Suspension (or ALIS) for Chronic Infection With Pseudomonas aeruginosa in People With Cystic Fibrosis for 2 years

Orkambi may improve liver disease in people with CF

Review of pregnancy in cystic fibrosis

Is elexacaftor/tezacaftor/ivacaftor always better than ezacaftor/ivacaftor?

CF Pancreatic Duct Secretions Can Alter Islet Function

Effect of elexacaftor-texacaftor-ivacaftor in cystic fibrosis patients with advanced lung disease

Complications relating to the heart and blood vessels in people with Cystic Fibrosis: A Review of the Literature

Different approaches to Aspergillus-related conditions in people with cystic fibrosis

first
previous
…
35
36
37
38
39
40
41
42
43
…
next
last